On Tuesday, Hologic (NASDAQ:HOLX) received a reaffirmation of a Buy rating and a $90.00 price target from Needham.
This assessment followed Hologic's fourth fiscal quarter 2024 performance, where the company's revenue exceeded market expectations, and earnings per share (EPS) aligned with consensus. Hologic's management has also provided revenue guidance for fiscal year 2025, which is slightly below consensus, while EPS guidance ranges around the expected consensus.
Hologic's organic sales growth, excluding COVID-related products, decelerated to 5.0% year-over-year in the fourth fiscal quarter, down from 5.8% in the third fiscal quarter. Despite this slowdown, the company witnessed broad-based growth across its product segments, including non-COVID Diagnostics, Breast Health, and GYN Surgical divisions.
The company's financial health was further indicated by an increase in gross margin by 110 basis points year-over-year and an operating margin increase of 170 basis points.
The firm noted that Hologic has largely moved beyond the headwinds caused by reduced COVID testing demand. For fiscal year 2025, Hologic anticipates its organic revenue growth to rebound to 2-3%, or 3-5% when excluding the impacts of COVID testing. This expected recovery includes the consideration of a lingering effect in the first fiscal quarter of 2025 from a ship-hold on Skeletal Health products.
In conclusion, Needham's analyst expressed confidence in Hologic's future performance, despite a modest downturn in revenue projections and a temporary impact from the Skeletal Health ship-hold. The analyst's reiterated Buy rating reflects a positive outlook for Hologic's recovery and growth in the upcoming fiscal year.
InvestingPro Insights
To complement Needham's positive outlook on Hologic (NASDAQ:HOLX), recent data from InvestingPro provides additional context to the company's financial position and market performance. Hologic's market capitalization stands at $19.45 billion, reflecting its significant presence in the healthcare sector. The company's P/E ratio of 28.49 suggests that investors are willing to pay a premium for its earnings, possibly due to growth expectations.
InvestingPro Tips highlight that Hologic's management has been aggressively buying back shares, which often signals confidence in the company's future prospects. This aligns with the analyst's positive stance on the stock. Additionally, Hologic operates with a moderate level of debt and has liquid assets exceeding short-term obligations, indicating a solid financial foundation as it moves into fiscal year 2025.
The company's stock is trading near its 52-week high, with a robust one-year price total return of 21.92% as of the latest data. This performance supports Needham's bullish view and $90 price target. For investors seeking more comprehensive analysis, InvestingPro offers 11 additional tips for Hologic, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.